Newsletter Tool

Today’s Big News

Jun 25, 2025

Kymera suffers Sanofi setback but secures $750M Gilead deal

Biogen’s Spinraza follow-up helps children with SMA who didn’t benefit from Zolgensma

Minovia brings back SPAC with plans to skate into icy public market

Bayer-owned BlueRock lays off 50 employees, shutters Cambridge research labs

FDA investigates patient deaths after treatment with Sarepta's Duchenne gene therapy Elevidys

Arbutus regains China rights to potential functional hep B cure as part of strategic rethink

Sangamo preps FDA application for Fabry gene therapy on heels of phase 1/2 registrational data

Featured

Kymera suffers Sanofi setback but secures $750M Gilead deal

By Nick Paul Taylor

Kymera Therapeutics sweetened news of a setback Wednesday, revealing that Sanofi is pulling back from its lead IRAK4 degrader alongside details of the selection of a follow-up prospect and a $750 million deal with Gilead.

Biogen’s Spinraza follow-up helps children with SMA who didn’t benefit from Zolgensma

By James Waldron

Biogen has pointed to an early readout from a small phase 1 trial as evidence that its antisense oligonucleotide salanersen could help children with spinal muscular atrophy (SMA) who are still struggling to sit independently despite having received Novartis’ Zolgensma.

Minovia brings back SPAC with plans to skate into icy public market

By Gabrielle Masson

While the IPO landscape remains icy, Minovia Therapeutics is skating into the market using a special purpose acquisition company (SPAC) road.

Bayer-owned BlueRock lays off 50 employees, shutters Cambridge research labs

By James Waldron

Bayer-owned BlueRock Therapeutics is laying off 50 employees and shuttering its research labs in Cambridge, Mass., in order to focus its resources on its priority cell therapies, a spokesperson said.

FDA investigates patient deaths after treatment with Sarepta's Duchenne gene therapy Elevidys

By Angus Liu

In one of the first major tests of the new FDA leadership’s regulatory philosophy toward gene therapies for rare diseases, the agency is investigating two Duchenne muscular dystrophy patient deaths following treatment with Sarepta Therapeutics’ Elevidys.

Arbutus regains China rights to potential functional hep B cure as part of strategic rethink

By James Waldron

Arbutus had made no secret of its desire to step up its plans for imdusiran. Now, the company has regained the China rights to the potential functional cure for hepatitis B.

Sangamo preps FDA application for Fabry gene therapy on heels of phase 1/2 registrational data

By Gabrielle Masson

Sangamo Therapeutics’ investigational gene therapy appears to improve kidney function at 52 weeks for patients with a rare genetic disorder.

RFK Jr. defends proposed HHS budget as Democrats slam cuts, gutting of CDC vaccine panel

By Heather Landi

HHS Secretary Robert F. Kennedy Jr. defended his reorganization of the agency and the proposed fiscal 2026 budget that cuts funding by 25% during a hearing Tuesday of the House Energy and Commerce Health subcommittee.

Novo Nordisk questioned over controversial Spanish obesity awareness campaign

By Nick Paul Taylor

Novo Nordisk is under fire over a Spanish obesity awareness campaign. After the campaign stirred up controversy, the Spanish ministry of health wrote to the drugmaker about a possible violation of drug advertising regulations.

Déjà vu for Bristol Myers as it faces another anti-competition lawsuit over blockbuster Pomalyst

By Kevin Dunleavy

Two months after Bristol Myers Squibb fended off a lawsuit which accused the drugmaker of using illegal tactics to protect its monopoly on multiple myeloma medicine Pomalyst, BMS is back in court, facing similar allegations from insurance giant Cigna over its strategy with the same treatment.

Fierce podcasts

Don’t miss an episode

AbbVie, ADCs and the future of cancer care

This week on "The Top Line," AbbVie’s Daejin Abidoye, M.D., joins us to discuss the future of antibody drug conjugates.

Hype and hope for AI in rural healthcare

Inside Fierce Medtech's Fierce 15

Resources

Executive Summary

Specialized Support to Accelerate Biotech Success

Biotech innovation doesn’t slow down—and neither should your lab partner. This brief outlines how early scientific engagement, operational transparency, and integrated global lab services help reduce risk, stay on schedule, and deliver results. Whether you're navigating your first trial or scaling a growing pipeline, see how a purpose-built lab model can help you move smarter and faster.